Patent ID: 6660257
Filing Date: 2003-12-09
Classification: A61K,A61P,C07K

Abstract:
A human flt-3 receptor agonist polypeptide, comprising a modified flt-3 ligand amino acid sequence selected from the group consisting of:(a) the sequence of SEQ ID NO: 144; and (b) a polypeptide comprising residues 1-132 of SEQ ID NO: 144; wherein said modification comprises the linear rearrangement of the sequences of (a) or (b); wherein the N-terminus is joined to the C-terminus directly or through a linker capable of joining the N-terminus to the C-terminus and new C- and N-termini are created between the amino acid residue pairs of SEQ ID NO: 144 selected from the group consisting of:28-29, 29-30, 30-31, 31-32, 32-33, 34-35, 36-37, 37-38, 38-39, 40-41, 41-42, 42-43, 64-65, 65-66, 66-67, 86-87, 88-89, 89-90, 90-91, 91-92, 92-93, 93-94, 94-95, 95-96, 96-97, 97-98, 98-99, 99-100, 100-101, 101-102, and 102-103; and wherein optionally said flt-3 receptor agonist polypeptide is immediately preceded by (methionineâˆ’1), (alanineâˆ’1) or (methionineâˆ’2, alanineâˆ’1).